Ceapro Inc V.CZO

I asked Copilot about marketing/distribution partners

[prophetoffactz]

Ceapro Inc., a Canadian biotechnology company, has developed a unique and standardized formulation for a healthy confection that includes a high concentration of oat beta-glucan (OBG). This formulation has received approval from Health Canada as a Novel Nutraceutical Product (NPN 80127493). The approved claims associated with this product include:

1. Reduction of LDL cholesterol
2. Supporting cardiovascular health
3. Reduction of Type 2 diabetes risks
4. Source of fiber for the maintenance of general good health
5. Support of a healthy digestive system

Given these substantial claims and the anticipated official commercial launch in the second half of 2024, major distributors and marketers in the health and wellness industry may indeed be interested in Ceapro’s product. While I don’t have an exhaustive list of specific companies, I can highlight a significant partnership that Ceapro has with a global provider of active ingredients:

• Symrise AG: Ceapro has an exclusive international supply and distribution agreement with Symrise AG, a German-based multinational. This agreement extends from 3 to 5 years until December 31, 2026. Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high-value active ingredients, including oat beta-glucan. The collaboration aims to reach major key international players in the cosmetic market1.

Additionally, as the oat beta-glucan market is projected to grow significantly, other major distributors and marketers may also express interest in Ceapro’s innovative product1. Keep in mind that exploring partnerships and reaching out to potential distributors and marketers directly would be essential for Ceapro’s successful market penetration.